3086 A Phase 1b study to evaluate the safety and antitumor activity of MEDI4736 in combination with tremelimumab in patients with advanced NSCLC. (September 2015) - Goldberg, S.B.; Balmanoukian, A.; Chaft, J.; Rizvi, N.; Sanborn, R.E.; Rebelatto, M.C.; Narwal, R.; Robbins, P.B.; Gu, Y.; Karakunnel, J.J.; Antonia, S.